OSE: Tedopi readout targeted for early 2028 as U.S. investor outreach begins
OSE targets an early 2028 readout for Tedopi's 363-patient registrational trial and reaches out to U.S. investors ahead of a possible Nasdaq listing.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, OSE's next steps for lusvertikimab include biomarker validation in pouchitis and ulcerative colitis. The registrational trial of Tedopi, which enrolls 363 patients, is expected to produce a readout in early 2028. Because near-term financing needs remain, OSE is approaching U.S. investors, and a dual listing on Nasdaq is possible in the future.
why it matters
Financing is the main driver here: a company that needs capital soon often has to find new shareholders in other markets. For OSE investors, the timing of the 2028 readout and the terms of any future deals will matter. The report does not change the company's current development plans.
tags
instruments
sources
- OSE: Tedopi targets an early 2028 readout as U.S. investor outreach seeks to advance development — TradingView, 20 October 2026 at 18:04 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗